Drug Discovery World

APRIL 17, 2024

Increasing gene expression via protein replacement or gene therapy has been shown to have limitations and drawbacks. CAMP4 is the only company modulating gene expression at the transcriptional level to increase mRNA production and thereby increase healthy protein production.

Science 147

Science RNA Disease Protein Expression 147

The Pharma Data

JANUARY 16, 2021

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform.

Protein Expression 52

Protein Expression Protein Production Production Drug Development 52

Drug Target Review

MARCH 15, 2024

As discussed above, recent advances in gene editing tools and transposon-based vectors have facilitated targeted and consistent cell line engineering for the development of protein expressing CHO cell lines. Cell Gene Therapy Insights 2017; 3(2), 131-158, 10.18609/cgti.2017.014. Budge JD, Knight TJ, Povey J, et al.

Engineering 104

Engineering Molecular Biology Protein Expression Medical Schools 104

Drug Discovery World

APRIL 30, 2024

Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43 mRNA-based approaches can produce proteins / peptides by using protein synthesis which is processed in a transfected cell 1.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Debets will present: ‘Selection and validation of TCR-like antibodies and TCRs for adoptive therapy’. from engineered peptide and antibody libraries’.

Engineering 162

Engineering Protein Expression Therapies Science 162

Drug Discovery World

NOVEMBER 9, 2023

These include: Samantha Bailey-Bucktrout, PhD, Senior Vice President, Akamis Bio, on: ‘Tumour specific immunogene therapy to deliver protein therapeutics to solid tumour microenvironments’. Chairperson Klampatsa on: ‘Overcoming tumour antigen heterogeneity in the context of car t cell therapy for solid tumours’.

Engineering 130

Engineering Protein Production Therapies Science 130

Drug Discovery World

NOVEMBER 30, 2023

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It It was by Nicholas Field, Principal Scientist, Purification Development, Lonza, titled: ‘Tailored CMC solutions to overcome the challenges in bispecific, Fab and Fc-fusion protein development programs’.

Protein Expression 147

Protein Expression Engineering DNA Therapies 147